林 脩涪

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Carcinoma 73%
3. Ovarian Neoplasms 71%
4. Carcinoma in Situ 63%
5. Neoplasms 49%
6. Endometrial Neoplasms 38%
7. Cytomegalovirus 37%
8. osimertinib 29%
9. Colorectal Neoplasms 29%
10. Epithelium 26%
11. Progressive Multifocal Leukoencephalopathy 25%
12. ErbB Receptors 25%
13. Endometrioid Carcinoma 24%
14. Retroelements 24%
15. Taiwan 23%
16. Real-Time Polymerase Chain Reaction 22%
17. Fallopian Tubes 22%
18. Pleura 21%
19. Adenocarcinoma of Lung 21%
20. Telomere 20%
21. Needle Biopsy 20%
22. Interleukin-17 19%
23. Kidney Transplantation 17%
24. Disease-Free Survival 17%
25. Cancer-Associated Fibroblasts 16%
26. Hyperplasia 16%
27. Mutation 16%
28. Prostatic Intraepithelial Neoplasia 16%
29. Methylation 15%
30. Prostate 15%
31. Leukemia 15%
32. Recurrence 15%
33. Hemoglobins 14%
34. Hysterectomy 13%
35. Veterans Hospitals 13%
36. Tomography 12%
37. Elderly 12%
38. Survival 12%
39. Lung 11%
40. Transplants 11%
41. Mitogen-Activated Protein Kinase Kinases 11%
42. Catenins 11%
43. trametinib 10%
44. Kidney 9%
45. General Hospitals 9%
46. Telomere Shortening 9%
47. Survival Rate 8%
48. Neoplasm Metastasis 7%
49. Scorpions 7%